Donate

Oncolink Features

Find My Cancer Drug

Cancer Types / Skin Cancers / Cutaneous T-Cell Lymphoma/Mycosis Fungoides / NCI Resources

NCI CANCERLIT^® Search: Cutaneous T-cell Lymphoma - June 2002

National Cancer Institute^®
Last Modified: June 1, 2002

Cutaneous eruption limited to skin covered by a swimming suit: mycosis fungoides.
Alopecia, hypohidrosis, and ulcerations in a man: mycosis fungoides.
Onset of non-AIDS Kaposi sarcoma during therapy with interferon alfa-2a in an 82-year-old man with concomitant cutaneous T-cell lymphoma.
Vitiligo-like leucoderma during photochemotherapy for mycosis fungoides.
Decreased expression of fas (APO-1/CD95) on lesional CD4+ T lymphocytes in cutaneous T cell lymphomas: correlations with blood data.
[Prognosis of primary cutaneous lymphomas]
Expression of intercellular adhesion molecule 3 (CDw50) on endothelial cells in cutaneous lymphomas. A comparative study between nodal and
ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis
Anaplastic large cell lymphoma: what's in a name?
Transformation in mycosis fungoides: the role of methotrexate.
Incidence of CTCL in Vietnam veterans.
Cutaneous T-cell lymphoma.
Is there a role for epigenetic factors in the pathogenesis of epidermotropic cutaneous T-cell lymphomas (mycosis fungoides and Sezary
Ichthyosiform mycosis fungoides.
Cutaneous dissemination of nasal NK/T-cell lymphoma with bone marrow, liver and lung involvement.
Treatment of cutaneous T cell lymphoma: current status and future directions.
Adult T-cell leukemia/lymphoma associated with HTLV-1 infection in a Brazilian adolescent.
The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells.
Epstein-Barr virus-positive blastoid nasal T/natural killer-cell lymphoma in a caucasian.
CD4+CD7- leukemic T cells from patients with Sezary syndrome are protected from galectin-1-triggered T cell death.
The role of interleukin-7 and interleukin-15 in cutaneous T-cell lymphoma.
Expression of selected T-cell antigens in the skin infiltration in primary cutaneous T-cell lymphomas.
Ultraviolet A1 (340-400 nm) phototherapy for cutaneous T-cell lymphoma.
Ultraviolet A1 (340-400 nm) phototherapy for cutaneous T-cell lymphoma?
[CD8-positive, CD30-negative cutaneous T-cell lymphoma simulating pyoderma gangrenosum]

1
UI - 11939818
AU - Grilli R; Soriano L; Farina C; Martin L; Requena L
TI - Cutaneous eruption limited to skin covered by a swimming suit: mycosis fungoides.
SO - Arch Dermatol 2002 Apr;138(4):527-32
AD - Fundacion Jimenez Diaz, Madrid, Spain.

2
UI - 11939819
AU - Hoefer HF; Chen SH; Duvic MA; Raimer SS
TI - Alopecia, hypohidrosis, and ulcerations in a man: mycosis fungoides.
SO - Arch Dermatol 2002 Apr;138(4):527-32
AD - University of Texas Medical Branch, Galveston, TX, USA.

3
UI - 11939825
AU - Giuliani M; Mastroianni A; Di Carlo A; Donati P; Miceli M; Monini P;
TI - Rezza G Onset of non-AIDS Kaposi sarcoma during therapy with interferon alfa-2a in an 82-year-old man with concomitant cutaneous T-cell lymphoma.
SO - Arch Dermatol 2002 Apr;138(4):535-7

4
UI - 11899124
AU - Mimouni D; David M; Feinmesser M; Coire CI; Hodak E
TI - Vitiligo-like leucoderma during photochemotherapy for mycosis fungoides.
SO - Br J Dermatol 2001 Dec;145(6):1008-14
AD - Department of Dermatology, Rabin Medical Centre, Petah Tikva, Israel. mimouni@post.tau.ac.il
We describe four patients with mycosis fungoides (MF) in whom depigmentation, and also leucotrichia in one, occurred following the resolution of the eruption during phototherapy (psoralen plus ultraviolet A treatment in three patients, climatotherapy in one). In all cases, the depigmentation was localized to the area of the pre-existing MF lesions. There was no clinically obvious phototoxicity. Biopsy study including S100 staining in all cases, and electron microscopy in one case, demonstrated the total absence of melanocytes, with no evidence of MF. It is suggested that the phototherapy may have activated a cell-mediated immunity leading to destruction of the melanocytes. We recommend that vitiligo-like leucoderma be added to the list of untoward effects of phototherapy in MF.

5
UI - 11899134
AU - Dereure O; Portales P; Clot J; Guilhou JJ
TI - Decreased expression of fas (APO-1/CD95) on lesional CD4+ T lymphocytes in cutaneous T cell lymphomas: correlations with blood data.
SO - Br J Dermatol 2001 Dec;145(6):1031-2

6
UI - 11937927
AU - Grange F; Bagot M
TI - [Prognosis of primary cutaneous lymphomas]
SO - Ann Dermatol Venereol 2002 Jan;129(1 Pt 1):30-40
AD - Service de Dermatologie, Hopital Pasteur, 68024 Colmar Cedex, France. florent.grange@ch-colmar.rss.fr
INTRODUCTION: The assessment of prognosis is a major step in the management of primary cutaneous lymphomas, as it allows to give patients an accurate information and it directs the treatment choice. MATERIAL AND METHODS: We performed a literature review of global prognosis and prognostic factors in primary cutaneous lymphomas. We used survival as the main endpoint, in particular specific survival and relative survival which provide accurate estimates of lymphoma-related deaths. Independent prognostic factors identified by multivariate survival analyses were emphasized. RESULTS: Overall prognosis of mycosis fungoides has improved during the past decades, possibly because of an increased proportion of cases diagnosed at early stages. Five-year disease-specific or relative survival rates of patients with T1 stage (patch/plaque disease<10 p. 100 of total skin surface), T2 (> 10 p. 100), T3 (tumor stage) and T4 (generalized erythroderma) are 100 p. 100, 67 to 96 p. 100, 51 to 80 p. 100 and 41 p. 100 respectively. Lymphomatoid papulosis and CD30+ primary cutaneous large T-cell lymphomas have an excellent prognosis, with 5-year survival rates of 100 p. 100 and 96 p. 100 respectively. CD30-negative primary cutaneous large T-cell lymphomas have an aggressive clinical behavior (5-year disease-specific or relative survival: 15 to 21 p. 100). Among primary cutaneous B-cell lymphomas, immunocytomas and marginal-zone B-cell lymphomas are not life-threatening. Follicle center-cell lymphomas that arise on the head and trunk have also an indolent clinical course (5-year specific survival rates: 94 to 97 p. 100). However, few of these lymphomas are composed of more than 50 p. 100 of large cells with round nuclei (centroblasts and/or immunoblasts) and may have a more aggressive clinical course (5-year specific survival: 72 p. 100). Large B-cell lymphomas of the leg often occur in older patients and have a poorer prognosis (5-year specific survival rate: 52 p. 100). Cases with a single lesion and those with a predominance of large cleaved cells (large centrocytes) have a more favorable clinical course than those with multiple tumors or a round cell morphology. CONCLUSION: Clinical, histological and immunophenotypical prognostic factors which have been identified so far may reliably predict the survival outcome in primary cutaneous lymphomas. On this basis, therapeutic guidelines have been proposed. These prognostic data will have to be taken into account when evaluating new potential prognostic factors (e.g. immunophenotypic or molecular) and performing prospective clinical trials.

7
UI - 9261475
AU - Dommann SN; Dommann-Scherrer CC; Ziegler T; Meyer J; Trueb RM; Kundig T;
TI - Panizzon R; Burg G Expression of intercellular adhesion molecule 3 (CDw50) on endothelial cells in cutaneous lymphomas. A comparative study between nodal and cutaneous lymphomas.
SO - Am J Dermatopathol 1997 Aug;19(4):391-5
AD - Department of Dermatology, University Hospital of Zurich, Switzerland.
Advances in the molecular definition of surface proteins (adhesion molecules) involved in tumor metastasis may help to explain the invasive behavior of malignant tumors, that is, the migration of tumor cells involving reversible adhesive contacts, their release in the circulation, and their extravasation into distant sites. Intercellular adhesion molecule-3 (ICAM-3), the third receptor for the lymphocyte function-associated antigen molecule-1 (LFA-1) was recently characterized. We investigated fresh frozen skin biopsies from 10 patients with mycosis fungoides, four with pleomorphic T-cell lymphoma, six with Sezary syndrome, 10 with primary cutaneous B-cell lymphoma, and 10 with eczematous lesions as controls. The biopsies were compared with lymph node biopsies of five patients with known cutaneous T-cell lymphoma (CTCL), 10 with primary nodal B-cell lymphoma, and 11 with lymph-node specimens showing dermatopathic lymphadenopathy as controls. The specimens were stained with ICAM-3 antibody (Bender Medical Science) using the alkaline phosphatase antialkaline phosphatase method. Using cytomorphologic criteria, neoplastic lymphocytes could be differentiated from smaller reactive cells. Staining intensities were classified semiquantitatively as follows: 4, strong expression in 75 to 100% of the tumor cells; 3, 50 to 75%; 2, 25 to 50%; 1, 5 to 25%; and 0 fewer than 5% of the tumor cells. The endothelial cells in skin biopsies of seven of 30 primary cutaneous lymphomas expressed ICAM-3. In contrast, no expression of ICAM-3 could be demonstrated on endothelial cells in lymph nodes infiltrated with tumor cells of CTCL. Finally, endothelial cells of lymph nodes infiltrated with primary nodal B-cell lymphomas showed expression of ICAM-3 in three of 10 patients. The endothelial cells in the 11 control patients presenting with both eczematous lesions and dermatopathic lymphadenopathy showed no staining for ICAM-3. Every patient who expressed ICAM-3 on endothelial cells showed systemic spread of this disease. The findings suggest that ICAM-3 expression may be induced on endothelial cells in late-stage cutaneous lymphomas, probably by a cytokine-mediated mechanism.

8
UI - 10911802
AU - ten Berge RL; Oudejans JJ; Ossenkoppele GJ; Pulford K; Willemze R;
TI - Falini B; Chott A; Meijer CJ ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination.
SO - J Clin Pathol 2000 Jun;53(6):445-50
AD - Department of Pathology, University Hospital Vrije Universiteit, Amsterdam, The Netherlands.
AIMS: In anaplastic large cell lymphoma (ALCL), the site of origin has been described as an important prognostic factor. Recently, a fusion protein containing anaplastic lymphoma kinase (ALK) was described in systemic nodal ALCL, and shown to be associated with a good prognosis. The aims of this study were to investigate whether the presence of ALK protein differs between ALCL of different sites of origin; to determine whether ALK expression occurs before dissemination to other sites; and, finally, to investigate whether the site of origin remains a prognostic parameter in ALK negative ALCL. METHODS: ALK expression, as detected by immunohistochemistry using the monoclonal antibodies ALK1 and ALKc, was studied in 85 ALCLs from different sites of origin. In 22 patients, ALK expression was studied in multiple biopsies from different sites (including 13 skin, 16 lymph node, and nine other). Overall survival time was analysed using the Kaplan Meier method. RESULTS: ALK expression was found in 20 of 51 systemic ALCLs with (primary) nodal involvement. No ALK expression was found in 15 primary cutaneous, 14 gastrointestinal, and five nasal ALCLs. Multiple and subsequent biopsies of patients showed ALK expression to be identical to that seen in the primary diagnostic biopsy. Kaplan Meier survival curves showed that in ALK negative ALCLs originating from different sites, primary cutaneous cases are associated with an excellent overall survival, whereas the other cases show a comparable five years survival of less than 40%. CONCLUSIONS: If present, ALK expression favours systemic ALCL with (primary) nodal involvement, and can be used in differentiating between extranodal involvement of systemic (nodal) ALCL and primary extranodal ALCL. ALK is expressed consistently in multiple biopsies of a given patient, indicating that the chromosomal abnormality leading to aberrant ALK expression occurs before dissemination to other sites. Finally, in ALK negative non-cutaneous ALCLs, different sites of origin show comparable poor survival.

9
UI - 11376029
AU - ten Berge RL; Oudejans JJ; Dukers DF; Meijer CJ
TI - Anaplastic large cell lymphoma: what's in a name?
SO - J Clin Pathol 2001 Jun;54(6):494-5

10
UI - 11992182
AU - Abd-el-Baki J; Demierre MF; Li N; Foss FM
TI - Transformation in mycosis fungoides: the role of methotrexate.
SO - J Cutan Med Surg 2002 Mar-Apr;6(2):109-16
AD - Department of Dermatology, Boston University School of Medicine, 720 Harrison Avenue, Boston, MA 02118, USA.
BACKGROUND: Large cell transformation in patients with mycosis fungoides (MF) has been well reported in the literature. Although the risk factors have not been clearly elucidated, advanced stage seems to be associated with a higher incidence of transformation. Because MF is a rare disorder, little is known about the influence of other factors such as immunosuppressive therapy in the occurrence of transformation. OBJECTIVE: We questioned the role of methotrexate (MTX) in the transformation of MF to large cell lymphoma (LCL). METHODS: We identified all patients with MF who were registered in our cutaneous lymphoma database. Transformation was defined by the presence of large cells exceeding 25% of the infiltrate in at least one skin biopsy. In one patient, we followed the histologic, immunophenotypic, and genotypic changes taking place as transformation occurred. Results: A total of 134 patients with MF were identified. Of 21 patients who received MTX, 3 transformed, and of the 113 patients in the non-MTX group, only 2 transformed. The incidence of transformation in the patients who received MTX was significantly higher than in those who did not receive the drug (14.3% vs. 1.8%; p = 0.03). This significance was maintained, even after controlling for stage and sex. For one patient who transformed, we demonstrated an identical dominant T-cell clone in all skin specimens, including the large cell lymphoma. CONCLUSION: Our results demonstrate a significant association between MTX exposure and transformation to LCL in patients with MF. In light of the small sample size, short followup of patients, and the inherent tendency of mycosis fungoides to transform, the role for MTX in transformation is unproven and needs to be confirmed in a multicenter study.

11
UI - 11887483
AU - Meyer KM
TI - Incidence of CTCL in Vietnam veterans.
SO - Dermatol Nurs 2002 Feb;14(1):42, 45, 52
AD - Photopheresis Unit, Morristown Memorial Hospital, Morristown, NJ, USA.
The causative factors of cutaneous T-cell lymphoma (CTCL) are unclear. Exposure to herbicides has been linked to the development of other lymphomas. Three Vietnam Veterans with CTCL treated at a photopheresis unit in New Jersey report positive histories of exposure to Agent Orange, a herbicide used during the war.

12
UI - 11887485
AU - Musse L
TI - Cutaneous T-cell lymphoma.
SO - Dermatol Nurs 2002 Feb;14(1):55
AD - Dermatology Clinic, National Institutes of Health, Bethesda, MD, USA.
The "Clinical Snapshot" series provides a concise examination of a clinical presentation including history, treatment, patient education, and nursing measures. Using the format here, you are invited to submit your "Clinical Snapshot" to Dermatology Nursing.

13
UI - 11920262
AU - Bachelez H
TI - Is there a role for epigenetic factors in the pathogenesis of epidermotropic cutaneous T-cell lymphomas (mycosis fungoides and Sezary syndrome)?
SO - Hematol J 2001;2(4):286-9
AD - Skin Research Insitute, Unite INSERM U532, Saint-Louis University Hospital, Assistance Publique-Hopitauz de Paris, Paris, France. herve.bachelez@sls.ap-hop-paris.fr

14
UI - 11937737
AU - Marzano AV; Borghi A; Facchetti M; Alessi E
TI - Ichthyosiform mycosis fungoides.
SO - Dermatology 2002;204(2):124-9
AD - Institute of Dermatological Sciences of the University of Milan and IRCCS Ospedale Maggiore of Milan, Italy. elvio.alessi@unimi.it
BACKGROUND: Mycosis fungoides (MF) is a skin malignancy of T helper lymphocytes with a wide clinical spectrum. Among the atypical variants of MF, there is an ichthyosis-like presentation. However, to date, only 1 case of ichthyosiform MF has been reported. OBJECTIVE: Our goal was to summarize the clinical characteristics and course, and the pathological, immunohistochemical and molecular genetic findings on 4 patients with ichthyosiform MF. METHODS: A retrospective study was conducted. RESULTS: The 4 patients represented 1.8% of the 221 patients with MF seen by us since 1975. None progressed to systemic disease in up to 12 years (median, 10 years) after the onset of the cutaneous manifestations. Interestingly, skin lesions typical of so-called follicular MF (FMF) were associated in 3 of 4 cases, whereas cutaneous manifestations of classic MF were absent in all 4 patients. CONCLUSION: Ichthyosiform MF represents a rare variant within the clinicopathologic spectrum of MF usually featuring a benign course and a tendency to be associated with lesions of FMF but not with lesions of classic MF. Copyright 2002 S. Karger AG, Basel

15
UI - 11952703
AU - Chang SE; Lee SY; Choi JH; Sung KJ; Moon KC; Koh JK
TI - Cutaneous dissemination of nasal NK/T-cell lymphoma with bone marrow, liver and lung involvement.
SO - Clin Exp Dermatol 2002 Mar;27(2):120-2
AD - Department of Dermatology, Asan Medical Center, College of Medicine, University of Ulsan, 388-1 Poongnap-dong, Songpa-gu, Seoul 138-736, Korea. cse@snu.md
We describe a 32-year-old Korean man with a primary nasal natural killer (NK)/T-cell lymphoma (NKTCL). Combination chemotherapy and radiotherapy resulted in initial complete remission. However, cutaneous dissemination to the trunk and proximal extremities occurred 16 months later and further investigations revealed involvement of the liver, lymph nodes, lung and bone marrow. Nasal CD56+ NKTCL is mostly localized to the nasal area but also shows a predilection for other sites, such as skin. Cutaneous dissemination may be an indicator of widespread metastasis to internal organs and is consistently fatal.

16
UI - 11978140
AU - Apisarnthanarax N; Talpur R; Duvic M
TI - Treatment of cutaneous T cell lymphoma: current status and future directions.
SO - Am J Clin Dermatol 2002;3(3):193-215
AD - Division of Internal Medicine, Department of Dermatology, University of Texas, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
The treatment of cutaneous T cell lymphoma (CTCL), which includes mycosis fungoides and Sezary syndrome, has been in a state of continual change over recent decades, as new therapies are constantly emerging in the search for more effective treatments for the disease. However, prognosis and survival of patients with CTCL remains dependent upon overall clinical stage (stage IA-IVB) at presentation, as well as response to therapy. Past therapies have been limited by toxicity or the lack of consistently durable responses, and few treatments have been shown to actually alter survival, especially in the late stages of disease. Even aggressive chemotherapy has not been shown to improve overall survival compared to conservative sequential therapy in advanced disease, and adds the risk of immunosuppressive complications. Over the last decade, extracorporeal photopheresis has been the only single treatment that has been shown to improve survival in patients with Sezary syndrome, although its true efficacy and place in combination therapy remain unclear. Much of the focus of current research has been on combinations of skin-directed therapies and biological response modifiers, which improve response rates. The results of various trials over the years have also brought into favor the use of post-remission maintenance therapy with topical corticosteroids, topical mechlorethamine (nitrogen mustard), interferon-alpha, or phototherapy to prevent disease relapse. Recent novel developments in CTCL therapy include oral bexarotene, a retinoid X receptor-selective retinoid that has activity in all stages of CTCL, and the topical gel formulation of bexarotene, which plays a role in treating localized lesions. US Food and Drug Administration (FDA)-approved, oral systemic bexarotene has the advantage of a 48% overall response rate at a dosage of 300 mg/m(2)/day, and avoids immunosuppression and risk of central line and catheter-related infectious complications that are associated with other systemic therapies. Monitoring of triglycerides and use of concomitant lipid-lowering agents and thyroid replacement is required in most patients. Also recently FDA-approved, denileukin diftitox is the first of a novel class of fusion toxin proteins and is selective for interleukin-2R (CD25+) T cells, targeting the malignant T cell clones in CTCL. Denileukin diftitox is associated with capillary leak syndrome in 20 to 30% of patients, which may be ameliorated by hydration and corticosteroids. Higher response rates are possible by combining bexarotene with "statin" drugs and active CTCL therapies. Studies are being conducted on combining bexarotene and denileukin diftitox with other modalities. Biological response modifier therapies that are in current or future investigational trials include topical tazarotene, pegylated interferon, interleukin-2, and interleukin-12. At the forefront of systemic chemotherapy development, pegylated liposomal doxorubicin, gemcitabine, and pentostatin appear to have the greatest potential for success in CTCL therapy. Bone marrow transplantation, which is currently limited by the risk of graft-versus-host disease, offers the greatest potential for disease cure. Further developments for CTCL may include more selective immunomodulatory agents, vaccines, and monoclonal antibodies.

17
UI - 11696852
AU - do Valle AC; Galhardo MC; Leite AC; Araujo AQ; Cuzzi-Maya T; Maceira JP;
TI - de Ameida Dobbin J Adult T-cell leukemia/lymphoma associated with HTLV-1 infection in a Brazilian adolescent.
SO - Rev Inst Med Trop Sao Paulo 2001 Sep-Oct;43(5):283-6
AD - Centro de Pesquisa Hospital Evandro Chagas, Fundacao Oswaldo Cruz, Rio de Janeiro, RJ, Brasil. afvalle@cpqhec.fiocruz.br
We present the case of a 15-year-old patient infected with HTLV-1 who developed a cutaneous T-cell lymphoma, confirmed by histopathological and immunohistochemical examination, as well as clinically and hematologically confirmed leukemia. The patient died 3 months after initial presentation of the disease. The rarity of the disease in this age group justifies the present report.

18
UI - 11929784
AU - Berger CL; Hanlon D; Kanada D; Dhodapkar M; Lombillo V; Wang N;
TI - Christensen I; Howe G; Crouch J; El-Fishawy P; Edelson R The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells.
SO - Blood 2002 Apr 15;99(8):2929-39
AD - Yale University, School of Medicine, Department of Dermatology and Laboratory Medicine, New Haven, CT 06510, USA. carole.berger@yale.edu
In the initial stage of cutaneous T-cell lymphoma (CTCL), proliferating CTCL cells are concentrated in the epidermis in close association with an immature dendritic cell (DC), the Langerhans cell. Because long-term in vitro culture of CTCL cells has proven difficult, the in vivo association with the major antigen-presenting cell (APC) of the epidermis has been postulated to play a role in directly stimulating the clonal T-cell proliferation. We report that CTCL cells can be reproducibly grown in culture for 3 months when cocultured with immature DCs. CTCL cells retain the phenotype and genotype of the initial malignant clone, whereas the APCs are a mixture of immature and mature DCs. CTCL cell and DC survival was dependent on direct membrane contact. Growth was inhibited by antibodies that bound to the T-cell receptor (TCR) or interfered with the interaction of CD40 with its ligand on the CTCL cell. Addition of antibody to CD3 or the clonotypic TCR caused rapid CTCL cell apoptosis followed by engulfment by avidly phagocytic immature DCs and subsequent DC maturation. The opportunity to study CTCL cells and immature DCs for prolonged periods will facilitate studies of tumor cell biology and will allow investigation of the intriguing hypothesis that CTCL cell growth is driven through TCR recognition of class II-presented self-peptides. In addition, the culture of CTCL cells will permit evaluation of therapies in vitro before clinical intervention, thereby improving safety and efficacy.

19
UI - 11966709
AU - Ling TC; Harris M; Craven NM
TI - Epstein-Barr virus-positive blastoid nasal T/natural killer-cell lymphoma in a caucasian.
SO - Br J Dermatol 2002 Apr;146(4):700-3
AD - Department of Dermatology, Burnley General Hospital, Burnley BB10 2PQ, U.K.
T/natural killer (NK)-cell lymphoma is a subtype of non-Hodgkin's lymphoma, with frequent cutaneous involvement; it follows an aggressive course. Most cases are reported in Asia, and typically present with nasopharyngeal involvement. There is a distinct variant known as blastoid T/NK-cell lymphoma, which affects elderly, non-Asian patients, with absence of nasal involvement. We report a middle-aged caucasian man who had blastoid T/NK-cell lymphoma with nasal involvement.

20
UI - 11986945
AU - Rappl G; Abken H; Muche JM; Sterry W; Tilgen W; Andre S; Kaltner H;
TI - Ugurel S; Gabius HJ; Reinhold U CD4+CD7- leukemic T cells from patients with Sezary syndrome are protected from galectin-1-triggered T cell death.
SO - Leukemia 2002 May;16(5):840-5
AD - Department of Dermatology, The Saarland University Hospital, 66421 Homburg/Saar, Germany.
In early stages of cutaneous T cell lymphoma (Sezary syndrome) both CD4+CD7- and CD4+CD7+ T cells clonally expand whereas in late stages of the disease CD7- cells are predominant in number, giving rise to the question whether CD7- T cells have a survival advantage in the skin. Galectin-1, a cell-bound lectin, was recently reported to trigger apoptosis in activated CD7+ T cells. Here, we demonstrate that in contrast to activated CD7(+) T cells, quiescent and activated CD69+ CD7- T cells from healthy donors and from Sezary patients are resistant to galectin-1-mediated cell death. CD7- T cells are apoptosis-resistant even during coculture with IFN-gamma-stimulated endothelial cells that constitutively express galectin-1 in high amounts. These data imply that resistance of CD7- T cells to galectin-1-induced apoptosis may contribute to the accumulation of CD7- Sezary T cells during progression of the disease.

21
UI - 12001911
AU - Zucker-Franklin D
TI - The role of interleukin-7 and interleukin-15 in cutaneous T-cell lymphoma.
SO - Blood 2002 May 1;99(9):3488; discussion 3488-9

22
UI - 11977317
AU - Wojnowska D; Lecewicz-Torun B; Chodorowska G; Juszkiewicz-Borowiec M;
TI - Skomra D Expression of selected T-cell antigens in the skin infiltration in primary cutaneous T-cell lymphomas.
SO - Ann Univ Mariae Curie Sklodowska [Med] 2001;56():237-42
AD - Department of Dermatology, Medical University of Lublin.
Skin biopsy specimens obtained from 16 patients with mycosis fungoides (MF) were examined immunohistochemically to assess phenotype of T-cells. Cases of benign chronic skin disorders (BCD) were included in control group. Examination of skin biopsies obtained from patients with MF revealed aberrant immunophenotypes of T-cells (loss of one or more of T-cell markers CD7, CD5, CD8, and rarely CD3). The expression of CD1a antigen both in the dermis and epidermis of the studied groups was similar and normal. No correlation between this loss of antigenicity and the prognosis was observed. These disturbances were seen in most of the cases of the early MF, but not seen in inflammatory skin diseases. In conclusion, the presence of aberrant immunophenotype of T-cells in skin infiltration may be useful in the diagnosis and differentiation of MF.

23
UI - 10411410
AU - Plettenberg H; Stege H; Megahed M; Ruzicka T; Hosokawa Y; Tsuji T;
TI - Morita A; Krutmann J Ultraviolet A1 (340-400 nm) phototherapy for cutaneous T-cell lymphoma.
SO - J Am Acad Dermatol 1999 Jul;41(1):47-50
AD - Department of Dermatology, Heinrich-Heine-University, Dusseldorf, Germany.
BACKGROUND: The results of a recent study suggested that ultraviolet A1 radiation (UVA1R; 340-400 nm) phototherapy for atopic dermatitis works through induction of apoptosis in skin-infiltrating helper T cells, indicating the possibility that other helper T cell-mediated skin diseases may respond to UVA1R as well. OBJECTIVE: The purpose of this open pilot study was to assess the therapeutic effectiveness of UVA1 phototherapy for cutaneous T-cell lymphoma (CTCL). METHODS: UVA1 phototherapy was used as monotherapy in patients (n = 3) with histologically proven CTCL (stages IA and IB). For daily whole body UVA1 irradiations, either a high-dose (n = 2; 130 J/cm2 UVA1 per exposure) or medium-dose (n = 1; 60 J/cm2 UVA1) regimen was used. Therapeutic effectiveness was assessed clinically and histologically. RESULTS: In each of the 3 patients, skin lesions began to resolve after only a few UVA1 radiation exposures. Complete clearance was observed between 16 and 20 exposures, regardless of whether the high- or medium-dose regimen had been employed. CONCLUSION: These studies suggest that patients with CTCL stages IA and IB can be treated effectively with UVA1 phototherapy.

24
UI - 11050602
AU - Stander H; Schwarz T
TI - Ultraviolet A1 (340-400 nm) phototherapy for cutaneous T-cell lymphoma?
SO - J Am Acad Dermatol 2000 Nov;43(5 Pt 1):881

25
UI - 11963190
AU - Dueck D; Hermes B; Audring H; Kohl PK
TI - [CD8-positive, CD30-negative cutaneous T-cell lymphoma simulating pyoderma gangrenosum]
SO - Hautarzt 2002 Feb;53(2):114-7
AD - Krankenhaus Neukolln, Abteilung fur Dermatologie und Venerologie, Rudower Strasse 48, 12351 Berlin.
Ulcerated primary cutaneous lymphomas are not rare, but the clinical manifestation as a pyoderma gangrenosum look-alike is extraordinary. CD8-positive lymphomas are rare, unclassifiable tumours with variable prognosis. We report on a 49-year-old patient with a large ulcerated primary cutaneous lymphoma on the left chest wall presenting as pyoderma gangrenosum. With immunohistochemical staining, most lymphocytes were shown to be CD8-positive. The CD30 antigen was not expressed. After radiotherapy with complete skin irradiation, the lymphoma regressed completely. The patient has been free of relapse for 28 months so far.

The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.

OncoLink I wish u knew...

Ms. Wagner discusses diet during cancer treatment and balancing nutritional needs and side effects. Read more.

Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet

Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies

Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer

Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults

OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews

Ask the Experts
Brown Bag Chat
Tracy's Corner

About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement

What's New RSS

Cancer Types

View by Cancer Types

Cancer Treatment

Cancer Risk and Prevention

Cancer Drugs

Support

Healthcare Professionals

Clinical Trials

Oncolink Features

Find My Cancer Drug

NCI CANCERLIT^® Search: Cutaneous T-cell Lymphoma - June 2002

Table of Contents

OncoLink I wish u knew...

Cancer Types

View by Cancer Types

Cancer Treatment

Cancer Risk and Prevention

Cancer Drugs

Support

Healthcare Professionals

Clinical Trials

Oncolink Features

Find My Cancer Drug

NCI CANCERLIT® Search: Cutaneous T-cell Lymphoma - June 2002

Table of Contents

OncoLink I wish u knew...

Find Your Cancer Drug - A

Find Your Cancer Drug - B

Find Your Cancer Drug - C

Find Your Cancer Drug - D

Find Your Cancer Drug - E

Find Your Cancer Drug - F

Find Your Cancer Drug - G

Find Your Cancer Drug - H

Find Your Cancer Drug - I

Find Your Cancer Drug - J

Find Your Cancer Drug - K

Find Your Cancer Drug - L

Find Your Cancer Drug - M

Find Your Cancer Drug - N

Find Your Cancer Drug - O

Find Your Cancer Drug - P

Find Your Cancer Drug - R

Find Your Cancer Drug - S

Find Your Cancer Drug - T

Find Your Cancer Drug - V

NCI CANCERLIT^® Search: Cutaneous T-cell Lymphoma - June 2002